A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 787
- Registration Number
- NCT02261493
- Locations
- 🇬🇧
The Bosham Clinic, Chichester, United Kingdom
🇬🇧The Gatehouse, Whitegate, United Kingdom
🇺🇸Steve Yoelin, MD Medical Associates, Inc., Newport Beach, California, United States
A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 421
- Registration Number
- NCT02261467
- Locations
- 🇺🇸
Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States
🇨🇦Sweat Clinics of Canada, Toronto, Ontario, Canada
🇨🇦Carruthers Dermatology Centre, Vancouver, British Columbia, Canada
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 528
- Registration Number
- NCT02250651
- Locations
- 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada
🇺🇸Mark B. Kislinger, MD, Inc., Glendora, California, United States
🇺🇸Southern California Eye Physicians and Surgeons, Los Alamitos, California, United States
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Allergan
- Target Recruit Count
- 594
- Registration Number
- NCT02247804
- Locations
- 🇺🇸
Nature Coast Clinical Research, Crystal River, Florida, United States
🇺🇸Montebello Medical Eye Center Inc., Montebello, California, United States
🇺🇸Glaucoma Institute of Beverly Hills, Los Angeles, California, United States
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 667
- Registration Number
- NCT02248844
- Locations
- 🇰🇷
Dr. Robbin Clinic, Gangnam-gu, Seoul, Korea, Republic of
A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT02245958
BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 176
- Registration Number
- NCT02230956
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 78
- Registration Number
- NCT02218034
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
- Conditions
- Interventions
- First Posted Date
- 2014-07-23
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 65
- Registration Number
- NCT02197806
BOTOX® in the Treatment of Crow's Feet Lines in China
- Conditions
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 417
- Registration Number
- NCT02195687